Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $36.00. Protect Your Portfolio ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

The launch of ONAPGO, a new growth product for Parkinson's disease, has shown encouraging initial responses from physicians. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a strong balance sheet ...

President and CEO of Supernus. "In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's ...

Supernus Pharmaceuticals Inc. (SUPN) reported its first-quarter 2025 earnings on May 6, revealing a net loss that fell short of analyst expectations. The company posted a GAAP net loss per share of $0 ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported a loss of $11.8 million in its first quarter. The Rockville, Maryland-based company said it ...